Multiple Myeloma News

• DLBCL: Major New Treatment Breakthroughs Recent significant breakthroughs for diffuse large B-cell lymphoma (DLBCL) have come through the use of CAR T-cell and immunotherapies and the FDA approval of polatuzumab for frontline DLBCL.
  MDedge News, May 18, 2023
• From War-Torn Beirut to Myeloma Research in NY Tarek Mouhieddine, MD, grew up in war-torn Lebanon and is now building a career studying multiple myeloma as a hem-onc in New York.
  MDedge News, April 20, 2023
• AACR 2023 Bispecific Antibody Provides Durable Remission in Myeloma REGN5459, designed to deplete plasma cells while mitigating the cytokine release syndrome, demonstrated deep and durable clinical responses in heavily pretreated relapsed/refractory myeloma.
  Medscape Medical News, April 19, 2023
• Outpatient Costs Top Drug Costs in Some Women With Breast Cancer Among a sample of younger women with invasive breast cancer and employer-sponsored insurance, outpatient-related out-of-pocket costs were greater than drug costs.
  MDedge News, April 10, 2023
• B-Cell Cancers: Sparse Insight Into Preventing Infections "We simply don't know" which preventive strategy is most effective, says expert. Patients will survive their cancers and "be at risk of infection or have significant cytopenias," she warned.
  MDedge News, April 06, 2023
• Mastocytosis: Rare, Underdiagnosed, Potentially Fatal Systemic mastocytosis is widely underdiagnosed, and many more hematologic oncologists should be looking for it, say experts.
  MDedge News, January 25, 2023
• Approvals and Withdrawals: Inside the Cancer Drug Terrain of 2022 Last year, the FDA approved almost a dozen novel cancer drugs and expanded indications for many more, while growing agency scrutiny led to numerous withdrawals.
  Medscape Medical News, January 23, 2023
• Multiple Myeloma Diagnosed More via Emergency Care During COVID The findings suggest that patients with multiple myeloma may have experienced delays in diagnosis. The study was published as a preprint and has not yet been peer reviewed.
  First Look, December 16, 2022
• ASH 2022 High Response Rates With Talquetamab in Advanced Myeloma The investigational, bispecific T-cell engager homes in on GPRC5D, a novel target unique to malignant plasma cells. It is awaiting approval from the Food and Drug Administration.
  Medscape Medical News, December 12, 2022
• Have You Heard of VEXAS Syndrome? The X-linked syndrome is a systemic autoinflammatory disease of undefined origin. It resists the classic therapeutic arsenal, but Janus kinase pathway inhibitors show promise as treatments.
  Medscape Medical News, December 09, 2022
• Teclistamab for MM: Lifesaver or 'Cause of Death'? Teclistamab (Tecvayli) has been approved for relapsed/refractory multiple myeloma patients who have received at least four lines of therapy; typically, such patients have just a few weeks to live.
  MDedge News, November 18, 2022
• New Vaccine Approach Halts Disease After 23 Yrs of Breast Cancer A combination of immune stimulants and immunotherapy that transforms tumors into cancer vaccine-producing factories has shown remarkable promise in a phase 1/2 trial, although only in 30% of patients.
  Medscape Medical News, November 17, 2022
• What's Medical About Marijuana? Most states have approved cannabis to treat forty-two diseases and conditions. And yet it remains a federally designated Schedule I drug (for now). So is it a scourge, a savior, or something in between?
  WebMD Health News, November 10, 2022
• 'Skyrocketing' Launch Prices for New Cancer Drug Need Reform Launch prices for new cancer drugs continue to escalate with no end in sight, putting breakthrough cures out of reach, concludes a new report from Congresswoman Katie Porter.
  Medscape Medical News, November 09, 2022
• Challenges of Artificial Intelligence Models in Thrombosis Data quality, quantity, and privacy are challenges for learning models in thrombosis. These emerging tools require more trained staff and patient input to become established in clinical practice.
  Medscape Medical News, November 08, 2022
• Cancer Drug Prices Not Tied to Clinical Benefit Cancer drug pricing is currently determined only by what the market can bear, and that needs to change, experts say.
  Medscape Medical News, October 31, 2022
• Cancer Death Rate in US Declining by 2% Every Year: Report The latest Annual Report to the Nation on the Status of Cancer notes that deaths from the disease have been falling by 2% from 2014 to 2019; the biggest decreases were in lung cancer and melanoma.
  Medscape Medical News, October 27, 2022
• ASTRO 2022 Bone Metastases Treated in a FLASH: One Dose of Proton RT The first-in-human trial of FLASH ultra-high-dose-rate proton radiotherapy shows that it offers pain relief with few toxicities to cancer patients with bone metastases.
  Medscape Medical News, October 25, 2022
• 'Plethora' of New MCL Treatment Options A "plethora of new agents" has transformed the treatment landscape for relapsed/refractory mantle cell lymphoma in recent years, notes an updated review.
  MDedge News, October 07, 2022
• CAR T-Cell Therapy Neurotoxicity Linked to NfL Elevations Patients who develop potentially serious neurotoxicity show elevated plasma levels of neurofilament light chain prior to the treatment, suggesting it could be predictor of risk for this side effect.
  MDedge News, October 06, 2022